Using genetics to understand why acute myeloid leukaemia cells don’t respond to treatment
Looking at the genetics of bone marrow samples to see which genes affect resistance to treatment.
Investigating how regulatory regions of the genome communicate with cancer causing genes
Finding which regulatory regions of the genome are causing leukaemia by acting on the wrong gene
Developing innovative models to support research for kinder treatments for B cell lymphoma
Glo-BNHL trial is an international trial that will recruit children across the globe with relapse BNHL and assign them to the trial to receive a novel therapy. We are requesting funds to conduct biological studies alongside the trial to improve our understanding of this cancer.
Understanding the evolution of neuroblastoma to improve treatment
Single-cell transcriptomics linked to lineage tracing to interrogate the role of intra-tumour heterogeneity in shaping therapeutic susceptibility and resistance in paediatric cancer
How does T-cell acute lymphoblastic leukaemia go to the brain?
Identifying drivers of central nervous system involvement in T-cell acute lymphoblastic leukaemia
Identifying the genetic changes in T-cell acute lymphoblastic leukaemia that fails to respond to chemotherapy
Deciphering the genomic landscape of childhood refractory t-cell acute lymphoblastic leukaemia
Towards chemotherapy-free treatment of lymphoid tumours in children with solid organ transplants
Towards chemotherapy-free treatment of paediatric post-transplant lymphoproliferative disorders
Understanding a potentially new therapeutic target in incurable childhood acute lymphoblastic leukaemia
Dissecting the role of CD133/PROM1 in MLL rearranged acute lymphoblastic leukaemia to develop novel targeted therapy
New markers to select children with cancer for trials with PARP inhibitors
Novel biomarkers for PARP inhibitor trials for children with cancer